As per the deal, Lonza will supply Mesoblast’s clinical and long-term commercial MPC product needs globally.
Mesoblast can trigger a process requiring Lonza to construct a purpose-built manufacturing facility exclusively for Mesoblast’s marketed products.
In return, Mesoblast will purchase agreed quantities of marketed products from the facility.
The agreement allows Mesoblast to have access to Lonza’s Cell Therapy facilities in Singapore to manufacture allogeneic cell therapy products, which is subject to certain exceptions.
However, Lonza is expected to use its proprietary intellectual property to facilitate reductions in Mesoblast’s manufacturing costs and help enable development of enhanced second generation products.